Harnessing the full power of the immune system

About us

Avidicure is pioneering an entirely new dual agonistic, multifunctional and avidity engineered antibody modality, “AVC-Boosters”, designed to safely deliver targeted and potent monotherapy, with broad applicability in oncology.

AVC-Boosters unlock strong and orchestrated immunological responses, harnessing the full power of both the innate and adaptive immune system.

The AVC-Booster design surpasses the best qualities of first-generation antibodies, checkpoint inhibitors, T-cell engagers and ADCs.

The Company is based in the Netherlands and supported by a syndicate of top-tier investors led by EQT-Life Sciences, and with BioGeneration Ventures as founding investor.

First-in-class rationally designed multifunctional antibodies

Platform

The fully owned proprietary AVC-Booster platform builds on a clinically proven antibody scaffold to which two proprietary co-stimulatory domains are genetically fused, triggering unique dual agonism, activating and modulating immune cells.

AVC-Boosters are avidity engineered to only stimulate  immune responses in the tumor. This unique specificity drives conditional activation, reduces toxicity risks and enhances the therapeutic window.

The AVC-Booster platform was designed combining decades of antibody engineering know-how, in silico design capabilities and immunology expertise. The platform offers seamless plug-and-play functionality for an entire generation of first-in-class products, by allowing for rapid and efficient swapping of binding domains targeting different antigens of interest. AVC-boosters can be manufactured in a scalable and cost-effective way using well-established antibody production platforms.